Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance Screening
Free accessResearch articleFirst published online October, 2016
Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance Screening
Use of direct-acting antiviral drugs (DAAs) that target HCV may be hampered by the rapid selection of viral strains that harbour drug resistance-associated variants (RAVs). These RAVs are often associated with a fitness cost and tend to occur on low-frequency strains within treatment-naive subjects. To address the clinical relevance of low frequency RAVs in the setting of DAAs, this study utilized a Primer ID ultra-deep sequencing approach to mitigate PCR errors and bias to accurately quantify viral sequences in subjects that failed DAA treatment.
Methods
Subjects were enrolled in the follow-up study P05063, and had previous treatment with boceprevir and all had detectable RAVs at virological failure (VF) based on Sanger-based population sequencing. Twelve subjects had three time points available: baseline, VF and follow-up (median 830.5 days). Viral RNA was amplified using unique primer identifiers (Primer IDs) and sequenced using 454 ultra-deep sequencing.
Results
The sequencing strategy used in this study improved the detection of clinically relevant low frequency strains bearing RAVs compared to population sequencing and showed that these strains can persist for up to 2 years post-treatment failure. Strains carrying multiple RAVs were common in breakthrough viruses. Putative compensatory mutations were identified.
Conclusions
The Primer ID ultra-deep sequencing approach identifies RAVs that can reduce drug sensitivity at levels below the detection threshold for population sequencing. The approach also removes PCR errors and biases, suggesting this sequencing strategy should become the standard approach by which to perform temporal quasispecies studies and resistance screening. ClinicalTrials.gov NCT00689390.
References
1.
RafiqS.M., BanikG.R., KhanS., RashidH., KhandakerG.Current burden of hepatitis C virus infection among injecting drug users: a mini systematic review of prevalence studies.Infect Disord Drug Targets2014; 14: 93–100.
2.
JensenD.M.A new era of hepatitis C therapy begins.N Engl J Med2011; 364: 1272–1274.
3.
SulkowskiM.S., GardinerD.F., Rodriguez-TorresM.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.N Engl J Med2014; 370: 211–221.
4.
KowdleyK.V., GordonS.C., ReddyK.R.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.N Engl J Med2014; 370: 1879–1888.
5.
AfdhalN., ZeuzemS., KwoP.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med2014; 370: 1889–1898.
6.
PoordadF., HezodeC., TrinhR.ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.N Engl J Med2014; 370: 1973–1982.
González-GrandeR., Jimenez-PerezM., Gonzalez ArjonaC., Mostazo TorresJ.New approaches in the treatment of hepatitis C.World J Gastroenterol2016; 22: 1421–1432.
11.
SarrazinC.The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.J Hepatol2016; 64: 486–504.
12.
NeumannA.U., LamN.P., DahariH.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.Science1998; 282: 103–107.
13.
GötteM.The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance.Curr Opin Virol2012; 2: 644–650.
14.
WelschC.Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.Drug Discov Today Technol2014; 11: 19–25.
15.
GaudieriS., RauchA., PfafferottK.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Hepatology2009; 49: 1069–1082.
16.
RongL., DahariH., RibeiroR.M., PerelsonA.S.Rapid emergence of protease inhibitor resistance in hepatitis C virus.Sci Transl Med2010; 2: 30ra2.
17.
ShimakamiT., WelschC., YamaneD.Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.Gastroenterology2011; 140: 667–675.
18.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients.Hepatology2008; 48: 1769–1778.
19.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.J Infect Dis2008; 198: 800–807.
20.
LenzO., FeveryB., VerbinnenT.Resistance analyses of HCV isolates from patients treated with simeprevir in Phase 2b/3 studies.64rd Annual Meeting of the American Association for the Study of Liver Diseases. 1–5 November 2013, Washington, DC, USA. Abstract 1101.
21.
ApplegateT.L., GaudieriS., PlauzollesA.Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.Antivir Ther2015; 20: 199–208.
22.
BarnardR.J., HoweJ.A., OgertR.A.Analysis of boceprevir resistance associated amino acid variants (RAVs) in two Phase 3 boceprevir clinical studies.Virology2013; 444: 329–336.
23.
HoweA.Y., LongJ., NickleD.Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.Antiviral Res2015; 113: 71–78.
24.
ShermanK.E., SulkowskiM.S., ZoulimF.Follow-up of SVR durability and viral resistance in patients with chronic hepatitis c treated with telaprevir-based regimens: interim analysis of the EXTEND study.62th Annual Meeting of the American Association for the Study of Liver Diseases. 6–9 November 2011, San Francisco, CA, USA.
25.
LeslieA.J., PfafferottK.J., ChettyP.HIV evolution: CTL escape mutation and reversion after transmission.Nat Med2004; 10: 282–289.
26.
FrancoS., TuralC., NevotM.Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.Gastroenterology2014; 147: 599–601 e1.
27.
BermanK., KwoP.Y.Boceprevir, an NS3 protease inhibitor of HCV.Clin Liver Dis2009; 13: 429–439.
28.
SusserS., WelschC., WangY.Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.Hepatology2009; 50: 1709–1718.
29.
TongX., ChaseR., SkeltonA., ChenT., Wright-MinogueJ., MalcolmB.A.Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.Antiviral Res2006; 70: 28–38.
30.
JabaraC.B., JonesC.D., RoachJ., AndersonJ.A., SwanstromR.Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.Proc Natl Acad Sci U S A2011; 108: 20166–20171.
31.
JabaraC.B., HuF., MollanK.R.Hepatitis C virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.Antimicrob Agents Chemother2014; 58: 6079–6092.
PondS.L., FrostS.D., MuseS.V.HyPhy: hypothesis testing using phylogenies.Bioinformatics2005; 21: 676–679.
34.
PfafferottK., DeshpandeP., McKinnonE.Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus.PLoS ONE2015; 10: e0130420.
35.
LarrubiaJ.R., Moreno-CuberoE., MiquelJ., Sanz-de-VillalobosE.Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.World J Gastroenterol2015; 21: 3480–3491.
36.
RauchA., JamesI., PfafferottK.Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure.Hepatology2009; 50: 1017–1029.
37.
DietzJ., SusserS., BerkowskiC., PernerD., ZeuzemS., SarrazinC.Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients.PLoS ONE2015; 10: e0134395.
38.
Le PogamS., SeshaadriA., KosakaA.Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.J Antimicrob Chemother2008; 61: 1205–1216.
39.
TsibrisA.M., KorberB., ArnaoutR.Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.PLoS ONE2009; 4: e5683.
40.
CampoD.S., DimitrovaZ., MitchellR.J., LaraJ., KhudyakovY.Coordinated evolution of the hepatitis C virus.Proc Natl Acad Sci U S A2008; 105: 9685–9690.
41.
GaudieriS., RauchA., ParkL.P.Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.J Virol2006; 80: 11094–11104.
42.
JohnM., MooreC.B., JamesI.R., MallalS.A.Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.Antivir Ther2005; 10: 551–555.
